An Immunohistochemical Study on the Expression of the Epidermal Growth Factor and Its Receptor in the Superficial Carcinoma of Esophagus.

Kōichi Tanaka, Chiaki Sano, Ryunosuke Kumashiro, S Yamasaki, Kazuaki Kido, Sadamitsu InutsukaThe Japanese Journal of Gastroenterological Surgery 1995 · DOI

Abstract

To more accurately predict the malignancy of superficial esophageal cancer, this study examined the expression of epidermal growth factor (EGF) and its receptor (EGFR) using immunohistochemical methods on paraffin sections. The study included 36 cases of untreated superficial esophageal cancer, with 32 cases of advanced esophageal cancer as controls. In superficial cancers, EGF expression was significantly higher in cases with deeper invasion (sm3 vs. mm/sm2) and in those with lymphatic invasion. Patients with high EGF expression had significantly lower postoperative survival rates. Cases expressing both EGF and EGFR showed a significantly higher rate of lymphatic invasion and poorer postoperative survival. Notably, all nine cases of recurrence exhibited EGF expression. These findings suggest that EGF and EGFR are expressed from the early stages of esophageal cancer, and EGF, in particular, may serve as a critical indicator for predicting prognosis and recurrence in superficial esophageal carcinoma.

Introduction

Superficial esophageal cancer, while often considered treatable, presents a clinical challenge due to a high postoperative recurrence and mortality rate (30–40%)—significantly higher than early-stage gastric or colorectal cancers. Current clinical management relies heavily on pathological staging, such as the depth of tumor invasion. However, these morphological markers often fail to capture the underlying biological aggressiveness of the tumor. This study investigates whether molecular markers, specifically the EGF/EGFR signaling pathway, can provide a more precise prediction of patient outcomes.

Methods: Immunohistochemical Analysis

The researchers employed immunohistochemistry (IHC) on paraffin-embedded tissue sections to visualize protein expression. This technique uses specific antibodies to bind to EGF and EGFR, which are then highlighted by a chromogen (staining them brown).

Immunohistochemical staining controls: (a) Submandibular gland (EGF positive), (b) Placental villi (EGF positive), and (c) A431 cells (EGFR positive).

A "positive" result was defined as protein expression in more than 51% of the tumor area. The study analyzed 36 superficial cases, 32 advanced cases, and 11 metastatic lymph nodes from patients treated between 1972 and 1992.

Key Findings

Early Expression and Tumor Depth

EGF and EGFR are not merely markers of advanced disease; they are present from the earliest stages of esophageal carcinoma. A significant correlation was found between the depth of invasion and EGF expression. While 0% of tumors confined to the mucous membrane were EGF-positive, 90% of tumors reaching the deepest submucosal layer (sm3) expressed the growth factor.

The Autocrine Loop and Aggressiveness

The co-expression of both EGF and its receptor (EGFR) was associated with the most aggressive tumor behavior. This "double positive" status likely indicates an autocrine loop where the tumor stimulates its own growth, leading to significantly higher rates of lymphatic invasion and poor survival.

Immunohistochemical staining of esophageal squamous cell carcinoma showing (a) EGF expression and (b) EGFR expression in the same tumor area.

Results and Prognostic Value

  • Survival Impact: The 4-year survival rate for EGF-positive patients was 40.0%, compared to 100% for EGF-negative patients.
  • Lymphatic Spread: EGF-positive tumors showed lymphatic invasion in 79.2% of cases, versus only 16.7% in EGF-negative cases.
  • Recurrence: Remarkably, 100% of patients who experienced recurrence (9/9) had EGF-positive primary tumors.

Discussion

The results demonstrate that EGF expression is a fundamental driver of esophageal cancer progression from its inception. Interestingly, the rate of EGF expression did not differ significantly between superficial (58%) and advanced (59%) cancers, suggesting its role is established early.

While the sample size is relatively small (n=36 for superficial cases), the statistical significance of the findings is robust. Future clinical applications could include using EGF/EGFR testing on preoperative biopsies to identify high-risk patients who may require more aggressive surgical or adjuvant therapies despite having "superficial" lesions.

Summary updated

Abstract

表在食道癌の悪性度をより的確に予測するために, パラフィン切片を用いた免疫組織学的方法で表在食道癌のepidermal growth factor (EGF) とepidermal growth factor receptor (EGFR) を検討した.対象は術前未治療の表在食道癌36例で, 進行食道癌32例をコントロールとした.表在癌では深達度がsm3がmm, sm2に比べ, またリンパ管侵襲陽性例が陰性例に比べEGFの発現が有意に高率であった.EGFの発現の強いものは弱いものより有意に術後生存率が低かった.EGFの発現は表在癌と進行癌の間に差はなかった.EGFとEGF-Rの両者とも発現する症例はリンパ管侵襲が有意に高率であり, 術後生存率は有意に不良であった.再発症例の9例はすべてEGFの発現がみられた.以上より, EGF, EGF-Rは表在食道癌の初期より発現していると考えられ, とくに, EGFは表在食道癌の予後, 再発を予測する重要な指針となる可能性のあることが示唆された.
BibTeX
@article{tanaka1995immunohistochemical,
  author = {Kōichi Tanaka and Chiaki Sano and Ryunosuke Kumashiro and S Yamasaki and Kazuaki Kido and Sadamitsu Inutsuka},
  title = {{An Immunohistochemical Study on the Expression of the Epidermal Growth Factor and Its Receptor in the Superficial Carcinoma of Esophagus.}},
  journal = {The Japanese Journal of Gastroenterological Surgery},
  year = {1995},
  doi = {10.5833/jjgs.28.2227},
}
Figure